Mäntylä R, Männistö PT, Vuorela A, Sundberg S, Ottoila P. Impairment of captopril bioavailability by concomitant food and antacid intake. Int J Clin Pharmacol Ther Toxicol (1984) 22, 626–9.
Singhvi SM, McKinstry DN, Shaw JM, Willard DA, Migdalof BH. Effect of food on the bioavailability of captopril in healthy subjects. J Clin Pharmacol (1982) 22, 135–40.
Öhman KP, Kågedal B, Larsson R, Karlberg BE. Pharmacokinetics of captopril and its effects on blood pressure during acute and chronic administration and in relation to food intake. J Cardiovasc Pharmacol (1985) 7 (Suppl 1), S20–S24.
Müller H-M, Overlack A, Heck I, Kolloch R, Stumpe KO. The influence of food intake on pharmacodynamics and plasma concentration of captopril. J Hypertens (1985) 3 (Suppl 2), S135–S136.
Salvetti A, Pedrinelli R, Magagna A, Abdel-Haq B, Graziadei L, Taddei S, Stornello M. Influence of food on acute and chronic effects of captopril in essential hypertensive patients. J Cardiovasc Pharmacol (1985) 7 (Suppl 1), S25–S29.
Mojaverian P, Rocci ML, Vlasses PH, Hoholick C, Clementi RA, Ferguson RK. Effect of food on the bioavailability of lisinopril, a nonsulfhydryl angiotensin-converting enzyme inhibitor. J Pharm Sci (1986) 75, 395–7.
Swanson BN, Vlasses PH, Ferguson RK, Bergquist PA, Till AE, Irvin JD, Harris K. Influence of food on the bioavailability of enalapril. J Pharm Sci (1984) 73, 1655–7.
Massarella JW, DeFeo TM, Brown AN, Lin A, Wills RJ. The influence of food on the pharmacokinetics and ACE inhibition of cilazapril. Br J Clin Pharmacol (1989) 27, 205S–209S.
Ferry JJ, Horvath AM, Sedman AJ, Latts JR, Colburn WA. Influence of food on the pharmacokinetics of quinapril and its active diacid metabolite, CI-928. J Clin Pharmacol (1987) 27,397–9.
Grass P, Gerbeau C, Kutz K. Spirapril: pharmacokinetic properties and drug interactions. Blood Pressure (1994) 3 (Suppl 2), 7–13.
Stimpel M, Cawello W. Pharmacokinetics and ACE-inhibition of the new ACE-inhibitor moexipril: is coadministration with food of clinical relevance? Hypertension (1995) 25, 1384.
Lecocq B, Funck-Brentano C, Lecocq V, Ferry A, Gardin M-E, Devissaguet M, Jaillon P. Influence of food on the pharmacokinetics of perindopril and the time course of angiotensin-converting enzyme inhibition in serum. Clin Pharmacol Ther (1990) 47, 397–402.
Vachharajani NN, Shyu WC, Mantha S, Park J-S, Greene DS, Barbhaiya RH. Lack of effect of food on the oral bioavailability of irbesartan in healthy male volunteers. J Clin Pharmacol (1998) 38, 433–6.
Marier J-F, Guilbaud R, Kambhampati SRP, Mathew P, Moberly J, Lee J, Salazar DE. The effect of AST-120 on the single-dose pharmacokinetics of losartan and losartan acid (E-3174) in healthy subjects. J Clin Pharmacol (2006) 46, 310–20.
Miller DS, Stirling JL, Yudkin J. Effect of ingestion of milk on concentrations of blood alcohol. Nature (1966) 212, 1051.
Fraser AG, Rosalki SB, Gamble GD, Pounder RE. Inter-individual and intra-individual variability of ethanol concentration-time profiles: comparison of ethanol ingestion before or after an evening meal. Br J Clin Pharmacol (1995) 40, 387–92.
Jones AW, Jönsson KÅ. Food-induced lowering of blood-ethanol profiles and increased rate of elimination immediately after a meal. J Forensic Sci (1994) 39, 1084–93.
Jones AW, Jönsson KÅ, Kechagias S. Effect of high-fat, high-protein, and high-carbohydrate meals on the pharmacokinetics of a small dose of ethanol. Br J Clin Pharmacol (1997) 44, 521–6.
Ramchandani VA, Kwo PY, Li T-K. Effect of food and food composition on alcohol elimination rates in healthy men and women. J Clin Pharmacol (2001) 41, 1345–50.
Helander A, Some M. Dietary serotonin and alcohol combined may provoke adverse physiological symptoms due to 5-hydroxytryptophol. Life Sci (2000) 67, 799–806.
Benton D, Nabb S. Breakfasts that release glucose at different speeds interact with previous alcohol intake to influence cognition and mood before and after lunch. Behav Neurosci (2004) 118, 936–43.
Wood JH. Effect of food on aspirin absorption. Lancet (1967) ii, 212.
Spiers ASD and Malone HF. Effect of food on aspirin absorption. Lancet (1967) i, 440.
Volans GN. Effects of food and exercise on the absorption of effervescent aspirin. Br J Clin Pharmacol (1974) 1, 137–41.
Stillings M, Havlik I, Chetty M, Clinton C, Schall R, Moodley I, Muir N, Little S. Comparison of the pharmacokinetic profiles of soluble aspirin and solid paracetamol tablets in fed and fasted volunteers. Curr Med Res Opin (2000) 16, 115–24.
Stempak D, Gammon J, Halton J, Champagne M, Koren G, Baruchel S. Modulation of celecoxib pharmacokinetics by food in pediatric patients. Clin Pharmacol Ther (2005) 77, 226–8.
Poli A, Moreno RA, Ribiero W, Dias HB, Moreno H, Muscara MN, De Nucci G. Influence of gastric acid secretion blockade and food intake on the bioavailability of a potassium diclofenac suspension in healthy male volunteers. Int J Clin Pharmacol Ther (1996) 34, 76–9.
Sioufi A, Stierlin H, Schweizer A, Botta L, Degen PH, Theobald W, Brechbühler S. Recent findings concerning clinically relevant pharmacokinetics of diclofenac sodium. In: Voltarol — New Findings, ed Kass E. Proc Int Symp Voltarol, Paris June 22nd (1981). 15th Int Congress of Rheumatology. p 19–30.
Troy S, Sanda M, Dressler D, Chiang S, Latts J. The effect of food and antacid on etodolac bioavailability. Clin Pharmacol Ther (1990) 47, 192.
McEwen J, De Luca M, Casini A, Gich I, Barbanoj MJ, Tost D, Artigas R, Mauleón D. The effect of food and an antacid on the bioavailability of dexketoprofen trometamol. J Clin Pharmacol (1998) 38 (Suppl), 41S–45S.
Pargal A, Kelkar MG, Nayak PJ. The effect of food on the bioavailability of ibuprofen and flurbiprofen from sustained release formulation. Biopharm Drug Dispos (1996) 17, 511–19.
Greenblatt DJ, von Moltke LL, Perloff ES, Luo Y, Harmatz JS, Zinny MA. Interaction of flurbiprofen with cranberry juice, grape juice, tea, and fluconazole: in vitro and clinical studies. Clin Pharmacol Ther (2006) 79, 125–33.
Levine MA, Walker SE, Paton TW. The effect of food or sucralfate on the bioavailability of S(+) and R(-) enantiomers of ibuprofen. J Clin Pharmacol (1992) 32, 1110–14.
Siemon D, de Vries JX, Stötzer F, Walter-Sack I, Dietl R. Fasting and postprandial disposition of R(-)- and S(+)-ibuprofen following oral administration of racemic drug in healthy individuals. Eur J Med Res (1997) 2, 215–19.
Klueglich M, Ring A, Scheuerer S, Trommeshauser D, Schuijt C, Liepold B, Berndl G. Ibuprofen extrudate, a novel, rapidly dissolving ibuprofen formulation: relative bioavailability compared to ibuprofen lysinate and regular ibuprofen, and food effect on all formulations. J Clin Pharmacol (2005) 45, 1055–61.
Caillé G, du Souich P, Besner JG, Gervais P, Vèzina M. Effects of food and sucralfate on the pharmacokinetics of naproxen and ketoprofen in humans. Am J Med (1989) 86 (Suppl 6A) 38–44. Correction. ibid. (1990) 89, 838.
Bannwarth B, Lapicque F, Netter P, Monot C, Tamisier JN, Thomas P, Royer RJ. The effect of food on the systemic availability of ketoprofen. Eur J Clin Pharmacol (1988) 33, 643–5.
Le Liboux A, Teule M, Frydman A, Oosterhuis B, Jonkman JHG. Effect of diet on the single- and multiple-dose pharmacokinetics of sustained-release ketoprofen. Eur J Clin Pharmacol (1994) 47, 361–6.
Eshra AG, Etman MA, Naggar VF. Effect of milk and food on the bioavailability of ketoprofen in man. Int J Pharmaceutics (1988) 44, 9–14.
Mroszczak E, Yee JP, Bynum L. Absorption of naproxen controlled-release tablets in fasting and postprandial volunteers. J Clin Pharmacol (1988) 28, 1128–31.
Palazzini E, Cristofori M, Babbini M. Bioavailability of a new controlled-release oral naproxen formulation given with and without food. Int J Clin Pharmacol Res (1992) 12, 179–84.
Forbes JA, Sandberg RÅ, Bood-Björklund L. The effect of food on bromfenac, naproxen sodium, and acetaminophen in postoperative pain after orthopedic surgery. Pharmacotherapy (1998) 18, 492–503.
Marzo A, Dal Bo L, Wool C, Cerutti R. Bioavailability, food effect and tolerability of S-naproxen betainate sodium salt monohydrate in steady state. Arzneimittelforschung (1998) 48, 935–40.
Emori HW, Paulus H, Bluestone R, Champion GD, Pearson C. Indomethacin serum concentrations in man. Effects of dosage, food, and antacid. Ann Rheum Dis (1976) 35, 333–8.
von Schrader HW, Buscher G, Dierdorf D, Mügge H, Wolf D. Nabumetone — a novel anti-inflammatory drug: the influence of food, milk, antacids, and analgesics on bioavailability of single oral doses. Int J Clin Pharmacol Ther Toxicol (1983) 21, 311–21.
Ishizaki T, Nomura T, Abe T. Pharmacokinetics of piroxicam, a new nonsteroidal anti-inflammatory agent, under fasting and postprandial states in man. J Pharmacokinet Biopharm (1979) 7, 369–81.
Tilstone WJ, Lawson DH, Omara F, Cunningham F. The steady-state pharmacokinetics of piroxicam: effect of food and iron. Eur J Rheumatol Inflamm (1981) 4, 309–13.
Day RO, Lam S, Paull P, Wade D. Effect of food and various antacids on the absorption of tenoxicam. Br J Clin Pharmacol (1987) 24, 323–8.
Busch U, Heinzel G, Narjes H. Effect of food on pharmacokinetics of meloxicam, a new non steroidal anti-inflammatory drug (NSAID). Agents Actions (1991) 32, 52–3.
Bhattacharjee M, Mathur R. Antinociceptive effect of sucrose ingestion in the human. Indian J Physiol Pharmacol (2005) 49, 383–94.
Jain R, Mukherjee K, Singh R. Influence of sweet tasting solutions on opioid withdrawal. Brain Res Bull (2004) 64, 319–22.
Musa MN, Lyons LL. Effect of food and liquid on the pharmacokinetics of propoxyphene. Curr Ther Res (1976) 19, 669–74.
Durnin C, Hind ID, Channon E, Yates DB, Cross M. Effect of food on the pharmacokinetics of oral immediate-release hydromorphone (Dilaudid® IR). Proc West Pharmacol Soc (2001) 44, 75–6.
Gourlay GK, Plummer JL, Cherry DA, Foate JA, Cousins MJ. Influence of a high-fat meal on the absorption of morphine from oral solutions. Clin Pharmacol Ther (1989) 46, 463–8.
Gourlay GK. Sustained relief of chronic pain. Pharmacokinetics of sustained release morphine. Clin Pharmacokinet (1998) 35, 173–90.
Drake J, Kirkpatrick CT, Aliyar CA, Crawford FE, Gibson P, Horth CE. Effect of food on the comparative pharmacokinetics of modified-release morphine tablet formulations: Oramorph SR and MST Continus. Br J Clin Pharmacol (1996) 41, 417–20.
Kaiko RF, Lazarus H, Cronin C, Grandy R, Thomas G, Goldenheim P. Controlled-release morphine bioavailability (MS Contin® tablets) in the presence and absence of food. Hosp J (1990) 6, 17–30.
Kaiko RF. The effect of food intake on the pharmacokinetics of sustained-release morphine sulfate capsules. Clin Ther (1997) 19, 296–303.
Broomhead A, West R, Eglinton L, Jones M, Bubner R, Sienko D, Knox K. Comparative single-dose pharmacokinetics of sustained-release and modified-release morphine sulfate capsules under fed and fasting conditions. Clin Drug Invest (1997) 13, 162–70.
Benziger DP, Kaiko RF, Miotto JB, Fitzmartin RD, Reder RF, Chasin M. Differential effects of food on the bioavailability of controlled-release oxycodone tablets and immediate-release oxycodone solution. J Pharm Sci (1996) 85, 407–10.
Raber M, Schulz H-U, Schürer M, Bias-Imhoff U, Momberger H. Pharmacokinetic properties of tramadol sustained release capsules. 2 nd communication: investigation of relative bioavailability and food interaction. Arzneimittelforschung (1999) 49, 588–93.
Robertson DRC, Higginson I, Macklin BS, Renwick AG, Waller DG, George CF. The influence of protein containing meals on the pharmacokinetics of levodopa in healthy volunteers. Br J Clin Pharmacol (1991) 31, 413–17.
Wessels JC, Koeleman HA, Boneschans B, Steyn HS. The influence of different types of breakfast on the absorption of paracetamol among members of an ethnic group. Int J Clin Pharmacol Ther Toxicol (1992) 30, 208–13.
Rostami-Hodjegan A, Shiran MR, Ayesh R, Grattan TJ, Burnett I, Darby-Dowman A, Tucker GT. A new rapidly absorbed paracetamol tablet containing sodium bicarbonate. A four-way crossover study to compare the concentration-time profile of paracetamol from the new paracetamol/sodium bicarbonate tablet and a conventional paracetamol tablet in fed and fasted volunteers. Drug Dev Ind Pharm (2002) 28, 523–31.
Walter-Sack IE, de Vries JX, Nickel B, Stenzhorn G, Weber E. The influence of different formula diets and different pharmaceutical formulations on the systemic availability of paracetamol, gallbladder size, and plasma glucose. Int J Clin Pharmacol Ther Toxicol (1989) 27, 544–50.
Holt S, Heading RC, Carter DC, Prescott LF, Tothill P. Effect of gel fibre on gastric emptying and absorption of glucose and paracetamol. Lancet (1979) 1, 636–9.
Forbes JA, Sandberg RA, Bood-Bjorklund L. The effect of food on bromfenac, naproxen sodium, and acetaminophen in postoperative pain after orthopedic surgery. Pharmacotherapy (1998) 18, 492–503.
Burnett I, Schachtel B, Sanner K, Bey M, Grattan T, Littlejohn S. Onset of analgesia of a paracetamol tablet containing sodium bicarbonate: a double-blind, placebo-controlled study in adult patients with acute sore throat. Clin Ther (2006) 28, 1273–8.
Prescott LF, Yoovathaworn K, Makarananda K, Saivises R, Sriwatanakul K. Impaired absorption of paracetamol in vegetarians. Br J Clin Pharmacol (1993) 36, 237–40.
Stillings M, Havlik I, Chetty M, Clinton C, Schall R, Moodley I, Muir N, Little S. Comparison of the pharmacokinetic profiles of soluble aspirin and solid paracetamol tablets in fed and fasted volunteers. Curr Med Res Opin (2000) 16, 115–24.
Whitcomb DC, Block GD. Association of acetaminophen hepatotoxicity with fasting and ethanol use. JAMA (1994) 272, 1845–50.
Schenker S, Speeg KV, Perez A, Finch J. The effects of food restriction in man on hepatic metabolism of acetaminophen. Clin Nutr (2001) 20, 145–50.
Pantuck EJ, Pantuck CB, Anderson KE, Wattenberg LW, Conney AH, Kappas A. Effect of brussels sprouts and cabbage on drug conjugation. Clin Pharmacol Ther (1984) 35, 161–9.
Chen L, Mohr SN, Yang CS. Decrease of plasma and urinary oxidative metabolites of acetaminophen after consumption of watercress by human volunteers. Clin Pharmacol Ther (1996) 60, 651–60.
Anderson KE, Schneider J, Pantuck EJ, Pantuck CB, Mudge GH, Welch RM, Conney AH, Kappas A. Acetaminophen metabolism in subjects fed charcoal-broiled beef. Clin Pharmacol Ther (1983) 34, 369–74.
Homeida M, Leahy W, Copeland S, Ali MMM, Harron DWG. Pharmacokinetic interaction between praziquantel and albendazole in Sudanese men. Ann Trop Med Parasitol (1994) 88, 551–9.
Nagy J, Schipper HG, Koopmans RP, Butter JJ, Van Boxtel CJ, Kager PA. Effect of grapefruit juice or cimetidine coadministration on albendazole bioavailability. Am J Trop Med Hyg (2002) 66, 260–3.
Dixon R, Pozniak AL, Watt HM, Rolan P, Posner J. Single-dose and steady-state pharmacokinetics of a novel microfluidized suspension of atovaquone in human immunodeficiency virus-seropositive patients. Antimicrob Agents Chemother (1996) 40, 556–60.
Falloon J, Sargent S, Piscitelli SC, Bechtel C, LaFon SW, Sadler B, Walker RE, Kovacs JA, Polis MA, Davey RT, Lan HC, Masur H. Atovaquone suspension in HIV-infected volunteers: pharmacokinetics, pharmacodynamics, and TMP-SMX interaction study. Pharmacotherapy (1999) 19, 1050–6.
Freeman CD, Klutman NE, Lamp KC, Dall LH, Strayer AH. Relative bioavailability of atovaquone suspension when administered with an enteral nutrition supplement. Ann Pharmacother (1998) 32, 1004–7.
Rolan PE, Mercer AJ, Weatherley BC, Holdich T, Meire H, Peck RW, Ridout G, Posner J. Examination of some factors responsible for a food-induced increase in absorption of atovaquone. Br J Clin Pharmacol (1994) 37, 13–20.
Zimmermann T, Yeates RA, Laufen H, Pfaff G, Wildfeuer A. Influence of concomitant food intake on the oral absorption of two triazole antifungal agents, itraconazole and fluconazole. Eur J Clin Pharmacol (1994) 46, 147–150.
Wishart JM. The influence of food on the pharmacokinetics of itraconazole in patients with superficial fungal infection. J Am Acad Dermatol (1987) 17, 220–3.
Carver P, Welage L, Kauffman C. The effect of food and gastric pH on the oral bioavailability of itraconazole in HIV+ patients. Intersci Conf Antimicrob Agents Chemother (1996) 36, 6.
Barone JA, Koh JG, Bierman RH, Colaizzi JL, Swanson KA, Gaffar MC, Moskovitz BL, Mechlinski W, Van De Velde V. Food interaction and steady-state pharmacokinetics of itraconazole capsules in healthy male volunteers. Antimicrob Agents Chemother (1993) 37, 778–84.
Barone JA, Moskovitz BL, Guarnieri J, Hassell AE, Colaizzi JL, Bierman RH, Jessen L. Food interaction and steady-state pharmacokinetics of itraconazole oral solution in healthy volunteers. Pharmacotherapy (1998) 18, 295–301.
Männistö PT, Mäntylä R, Nykänen S, Lamminsivu U, Ottoila P. Impairing effect of food on ketoconazole absorption. Antimicrob Agents Chemother (1982) 21, 730–33.
Lelawongs P, Barone JA, Colaizzi JL, Hsuan ATM, Mechlinski W, Legendre R, Guarnieri J. Effect of food and gastric acidity on absorption of orally administered ketoconazole. Clin Pharm (1988) 7, 228–35.
Daneshmend TK, Warnock DW, Ene MD, Johnson EM, Potten MR, Richardson MD, Williamson PJ. Influence of food on the pharmacokinetics of ketoconazole. Antimicrob Agents Chemother (1984) 25, 1–3.
Courtney R, Sansone A, Calzetta A, Martinho M, Laughlin. The effect of a nutritional supplement (Boost Plus) on the oral bioavailability of posaconazole. Intersci Conf Antimicrob Agents Chemother (2003) 43, 33.
Courtney R, Wexler D, Radwanski E, Lim J, Laughlin M. Effect of food on the relative bioavailability of two oral formulations of posaconazole in healthy adults. Br J Clin Pharmacol (2004) 57, 218–22.
Purkins L, Wood N, Kleinermans D, Greenhalgh K, Nichols D. Effect of food on the pharmacokinetics of multiple-dose oral voriconazole. Br J Clin Pharmacol (2003) 56 (Suppl 1) 17–23.
Bindschedler M, et al. Comparative bioavailability of benflumetol after administration of single oral doses of co-artemether under fed and fasted conditions to healthy subjects. Cited in Lefèvre G, Thomsen MS. Clinical Pharmacokinetics of artemether and lumefantrine (Riamet®). Clin Drug Invest (1999) 18, 467–80.
Ezzet F, van Vugt M, Nosten F, Looareesuwan S, White NJ. Pharmacokinetics and pharmacodynamics of lumefantrine (Benflumetol) in acute falciparum malaria. Antimicrob Agents Chemother (2000) 44, 697–704.
Khalafalla N, Elgholmy ZA, Khalil SA. Influence of a high fat diet on GI absorption of griseofulvin tablets in man. Pharmazie (1981) 36, 692–3.
Crounse RG. Human pharmacology of griseofulvin: the effect of fat intake on gastrointestinal absorption. J Invest Dermatol (1961) 37, 529–33.
Crounse RG. Effective use of griseofulvin. Arch Dermatol (1963) 87, 176–8.
Ogunbona FA, Smith IF, Olawoye OS. Fat contents of meals and bioavailability of griseofulvin in man. J Pharm Pharmacol (1985) 37, 283–4.
Aoyagi N, Ogata H, Kaniwa N, Ejima A. Effect of food on the bioavailability of griseofulvin from microsize and PEG ultramicrosize (GRIS-PEG) plain tablets. J Pharmacobiodyn (1982) 4, 120–4.
Bijanzadeh M, Mahmoudian M, Salehian P, Khazainia T, Eshghi L, Khosravy A. The bioavailability of griseofulvin from microsized and ultramicrosized tablets in nonfasting volunteers. Indian J Physiol Pharmacol (1990) 34, 157–61.
Bates TR, Sequeria JA. Bioavailability of micronized griseofulvin from corn oil-in-water emulsion, aqueous suspension, and commercial tablet dosage forms in humans. J Pharm Sci (1975) 64, 793–7.
Khalafalla N, Elgholmy ZA, Khalil SA. Influence of a high fat diet on GI absorption of griseofulvin tablets in man. Pharmazie (1981) 36, 692–3.
Crounse RG. Human pharmacology of griseofulvin: the effect of fat intake on gastrointestinal absorption. J Invest Dermatol (1961) 37, 529–33.
Crounse RG. Effective use of griseofulvin. Arch Dermatol (1963) 87, 176–8.a!.
Ogunbona FA, Smith IF, Olawoye OS. Fat contents of meals and bioavailability of griseofulvin in man. J Pharm Pharmacol (1985) 37, 283–4.
Aoyagi N, Ogata H, Kaniwa N, Ejima A. Effect of food on the bioavailability of griseofulvin from microsize and PEG ultramicrosize (GRIS-PEG) plain tablets. J Pharmacobiodyn (1982) 4, 120–4.
Bijanzadeh M, Mahmoudian M, Salehian P, Khazainia T, Eshghi L, Khosravy A. The bioavailability of griseofulvin from microsized and ultramicrosized tablets in nonfasting volunteers. Indian J Physiol Pharmacol (1990) 34, 157–61.
Bates TR, Sequeria JA. Bioavailability of micronized griseofulvin from corn oil-in-water emulsion, aqueous suspension, and commercial tablet dosage forms in humans. J Pharm Sci (1975) 64, 793–7.
Castro N, Medina R, Sotelo J, Jung H. Bioavailability of praziquantel increases with concomitant administration of food. Antimicrob Agents Chemother (2000) 44, 2903–4.
Homeida M, Leahy W, Copeland S, Ali MM, Harron DWG. Pharmacokinetic interaction between praziquantel and albendazole in Sudanese men. Ann Trop Med Parasitol (1994) 88, 551–9.
Castro N, González-Esquivel DF, López M, Jung H. Análisis comparativo de la influencia de los alimentos y la cimetidina en los niveles plasmáticos de prazicuantel. Rev Invest Clin (2003) 55, 655–61.
Tjandra-Maga TB, Verbesselt R, Van Hecken A, Mullie A, De Schepper PJ. Flecainide: single and multiple oral dose kinetics, absolute bioavailability and effect of food and antacid in man. Br J Clin Pharmacol (1986) 22, 309–16.
Russell GAB, Martin RP. Flecainide toxicity. Arch Dis Child (1989) 64, 860–2.
Karim S, Ahmed T, Monif T, Saha N, Sharma PL. The effect of four different types of food on the bioavailability of cefaclor. Eur J Drug Metab Pharmacokinet (2003), 28, 185–90.
Khan BAH, Ahmed T, Karim S, Monif T, Saha N. Comparative effect of different types of food on the bioavailability of cefaclor extended release tablet. Eur J Drug Metab Pharmacokinet (2004) 29, 125–32.
Blouin RA, Kneer J, Stoeckel K. Pharmacokinetics of intravenous cefetamet (Ro 15-8074) and oral cefetamet pivoxil (R0-8075) in young and elderly subjects. Antimicrob Agents Chemother (1989) 33, 291–6.
Koup JR, Dubach UC, Brandt R, Wyss R, Stoeckel K. Pharmacokinetics of cefetamet (Ro 15-8074) and cefetamet pivoxil (Ro 15-8075) after intravenous and oral doses in humans. Antimicrob Agents Chemother (1988) 32, 573–9.
Tam YK, Kneer J, Dubach UC, Stoeckel K. Effects of timing of food and fluid volume on cefetamet pivoxil absorption in healthy normal volunteers. Antimicrob Agents Chemother (1990) 34, 1556–9.
Faulkner RD, Bohaychuk W, Haynes JD, Desjardins RE, Yacobi A, Silber BM. The pharmacokinetics of cefixime in the fasted and fed state. Eur J Clin Pharmacol (1988) 34, 525–8.
Borin MT, Driver MR, Forbes KK. Effect of timing of food on absorption of cefpodoxime proxetil. J Clin Pharmacol (1995) 35, 505–9.
Hughes GS, Heald DL, Barker KB, Patel RK, Spillers CR, Watts KC, Batts DH, Euler AR. The effects of gastric pH and food on the pharmacokinetics of a new oral cephalosporin, cefpodoxime proxetil. Clin Pharmacol Ther (1989) 46, 674–85.
Borin MT, Forbes KK. Effect of food on absorption of cefpodoxime proxetil oral suspension in adults. Antimicrob Agents Chemother (1995) 39, 273–5.
Shukla UA, Pittman KA, Barbhaiya RH. Pharmacokinetic interactions of cefprozil with food, propantheline, metoclopramide, and probenecid in healthy volunteers. J Clin Pharmacol (1992) 32, 725–31.
Mischler TW, Sugerman AA, Willard DA, Brannick LJ, Neiss ES. Influence of probenecid and food on the bioavailability of cephradine in normal male subjects. J Clin Pharmacol (1974) 14, 604–11.
Finn A, Straughn A, Meyer M, Chubb J. Effect of dose and food on the bioavailability of cefuroxime axetil. Biopharm Drug Dispos (1987) 8, 519–26.
Sommers DK, Van Wyk M, Moncrieff J, Schoeman HS. Influence of food and reduced gastric acidity on the bioavailability of bacampicillin and cefuroxime axetil. Br J Clin Pharmacol (1984) 18, 535–9.
McCall CE, Steigbigel NH, Finland M. Lincomycin: activity in vitro and absorption and excretion in normal young men. Am J Med Sci (1967) 254, 144–55.
Kaplan K, Chew WH, Weinstein L. Microbiological, pharmacological and clinical studies of lincomycin. Am J Med Sci (1965) 250, 137–46.
McGehee RF, Smith CB, Wilcox C, Finland M. Comparative studies of antibacterial activity in vitro and absorption and excretion of lincomycin and clinimycin. Am J Med Sci (1968) 256, 279–92.
Wagner JG, Novak E, Patel NC, Chidester CG, Lummis WL. Absorption, excretion and halflife of clinimycin in normal adult males. Am J Med Sci (1968) 256, 25–37.
Wagner JG. Aspects of pharmacokinetics and biopharmaceutics in relation to drug activity. Am J Pharm Sci Support Public Health (1969) 141, 5–20.
Zhu M, Nix DE, Adam RD, Childs JM, Peloquin CA. Pharmacokinetics of cycloserine under fasting conditions and with high-fat meal, orange juice, and antacids. Pharmacotherapy (2001) 21, 891–7.
Melander A, Danielson K, Hanson A, Jansson L, Rerup C, Scherstén B, Thulin T, Wåhlin E. Reduction of isoniazid bioavailability in normal men by concomitant intake of food. Acta Med Scand (1976) 200, 93–7.
Peloquin CA, Namdar S, Dodge AA, Nix DE. Pharmacokinetics of isoniazid under fasting conditions, with food, and with antacids. Int J Tuberc Lung Dis (1999) 3, 703–710.
Männisto P, Mäntylä R, Klinge R, Nykänen S, Koponen A, Lamminsivu U. Influence of various diets on the bioavailability of isoniazid. J Antimicrob Chemother (1982) 10, 427–34.
Welshman IR, Sisson TA, Jungbluth GL, Stalker D, Hopkins NK. Linezolid absolute bioavailability and the effect of food on oral bioavailability. Biopharm Drug Dispos (2001) 22, 91–7.
Islinger F, Dehghanyar P, Sauermann R, Burger C, Kloft C, Muller M, Joukhader C. The effect of food on plasma and tissue concentrations of linezolid after multiple doses. Int J Antimicrob Agents (2006) 27, 108–12.
Milton K, Edwards G, Ward SA, Orme ML’E, Breckenridge AM. Pharmacokinetics of halofantrine in man: effects of food and dose size. Br J Clin Pharmacol (1989) 28, 71–7.
Welling PG, Huang H, Koch PA, Craig WA, Madsen PO. Bioavailability of ampicillin and amoxicillin in fasted and nonfasted subjects. J Pharm Sci (1977) 66, 549–52.
Eshelman FN, Spyker DA. Pharmacokinetics of amoxicillin and ampicillin: crossover study of the effect of food. Antimicrob Agents Chemother (1978) 14, 539–43.
Staniforth DH, Lillystone RJ, Jackson D. Effect of food on the bioavailability and tolerance of clavulanic acid/amoxycillin combination. J Antimicrob Chemother (1982) 10, 131–9.
Roller S, Lode H, Stelzer I, Deppermann KM, Boeckh M, Koeppe P. Pharmacokinetics of loracarbef and interaction with acetylcysteine. Eur J Clin Microbiol Infect Dis (1992) 11, 851–5.
DeSante KA, Zeckel ML. Pharmacokinetic profile of loracarbef. Am J Med (1992) 92 (Suppl 6A), 16S–19S.
Höffken G, Lode H, Wiley R, Glatzel TD, Sievers D, Olschewski T, Borner K, Koeppe T. Pharmacokinetics and bioavailability of ciprofloxacin and ofloxacin: effect of food and antacid intake. Rev Infect Dis (1988) 10 (Suppl 1), S138–S139.
Frost RW, Carlson JD, Dietz AJ, Heyd A, Lettieri JT. Ciprofloxacin pharmacokinetics after a standard or high-fat/high-calcium breakfast. J Clin Pharmacol (1989) 29, 953–5.
Verho M, Malerczyk V, Dagrosa E, Korn A. The effect of food on the pharmacokinetics of ofloxacin. Curr Med Res Opin (1986) 10, 166–71.
Dudley MN, Marchbanks CR, Flor SC, Beals B. The effect of food or milk on the absorption kinetics of ofloxacin. Eur J Clin Pharmacol (1991) 41, 569–71.
Hooper WD, Dickinson RG, Eadie MJ. Effect of food on absorption of lomefloxacin. Antimicrob Agents Chemother (1990) 34, 1797–9.
Somogyi AA, Bochner F, Keal JA, Rolan PE, Smith M. Effect of food on enoxacin absorption. Antimicrob Agents Chemother (1987) 31, 638–9.
Allen A, Bygate E, Clark D, Lewis A, Pay V. The effect of food on the bioavailability of oral gemifloxacin in healthy volunteers. Int J Antimicrob Agents (2000) 16, 45–50.
Johnson RD, Dorr MB, Hunt TL, Jensen BK, Talbot GH. Effects of food on the pharmacokinetics of sparfloxacin. Clin Ther (1999) 21, 982–91.
Polasa K, Krishnaswamy K. Effect of food on bioavailability of rifampicin. J Clin Pharmacol (1983) 23, 433–7.
Peloquin CA, Namdar R, Singleton MD, Nix DE. Pharmacokinetics of rifampin under fasting conditions, with food, and with antacids. Chest (1999) 155, 12–18.
Hoppu K, Tuomisto J, Koskimies O and Simell O. Food and guar decrease absorption of trimethoprim. Eur J Clin Pharmacol (1987) 32, 427–9.
Melander A, Wåhlin E. Enhancement of dicoumarol bioavailability by concomitant food intake. Eur J Clin Pharmacol (1978) 14, 441–4.
Simon LS, Likes KE. Hypoprothrombinemic response due to ice cream. Drug Intell Clin Pharm (1978) 12, 121–2.
Blackshaw CA, Watson VA. Interaction between warfarin and ice cream. Pharm J (1990) 244, 318.
Gidal BE, Maly MM, Budde J, Lensmeyer GL, Pitterle ME, Jones JC. Effect of a high-protein meal on gabapentin pharmacokinetics. Epilepsy Res (1996) 23, 71–6.
Gidal BE, Maly MM, Kowalski JW, Rutecki PA, Pitterle ME, Cook DE. Gabapentin absorption: effect of mixing with foods of varying macronutrient composition. Ann Pharmacother (1998) 32, 405–9.
Parnell J, Sheth R, Limdi N, Gidal BE. Oral absorption of gabapentin syrup is not impaired by concomitant administration with various beverages or enteral nutrition supplement. Epilepsia (2001) 42 (Suppl 7), 91.
Fay MA, Sheth RD, Gidal BE. Oral absorption kinetics of levetiracetam: the effect of mixing with food or enteral nutrition formulas. Clin Ther (2005) 27, 594–8.
Jann MW, Bean J, Fidone G. Interaction of dietary pudding with phenytoin. Pediatrics (1986) 78, 952–3.
Melander A, Brante G, Johansson Ö, Lindberg T, Wåhlin-Boll E. Influence of food on the absorption of phenytoin in man. Eur J Clin Pharmacol (1979) 15, 269–74.
Johansson Ö, Wahlin-Boll E, Lindberg T, Melander A. Opposite effects of carbohydrate and protein on phenytoin absorption in man. Drug Nutr Interact (1983) 2, 139–44.
Sekikawa H, Nakano M, Takada M, Arita T. Influence of dietary components on the bioavailability of phenytoin. Chem Pharm Bull (Tokyo) (1980) 28, 2443–9.
Kennedy MC, Wade DN. The effect of food on the absorption of phenytoin. Aust N Z J Med (1982) 12, 258–61.
Longe RL, Smith OB. Phenytoin interaction with an oral feeding results in loss of seizure control. J Am Geriatr Soc (1988) 36, 542-4.
Taylor DM, Massey CA, Willson WG, Dhillon S. Lowered serum phenytoin concentrations during therapy with liquid food concentrates. Ann Pharmacother (1993) 27, 369.
Marvel ME, Bertino JS. Comparative effects of an elemental and a complex enteral feeding formulation on the absorption of phenytoin suspension. J Parenter Enteral Nutr (1991) 15, 316–8.
Nishimura LY, Armstrong EP, Plezia PM, Iacono RP. Influence of enteral feedings on phenytoin sodium absorption from capsules. Drug Intell Clin Pharm (1988) 22, 130–3.
Guidry JR, Eastwood TF, Curry SC. Phenytoin absorption in volunteers receiving selected enteral feedings. West J Med (1989) 150, 659–61.
Summers VM, Grant R. Nasogastric feeding and phenytoin interaction. Pharm J (1989) 243, 181.
Bauer LA. Interference of oral phenytoin absorption by continuous nasogastric feedings. Neurology (1982) 32, 570–2.
Ozuna J, Friel P. Effect of enteral tube feeding on serum phenytoin levels. J Neurosurg Nurs (1984) 16, 289–91.
Pearce GA. Apparent inhibition of phenytoin absorption by an enteral nutrient formula. Aust J Hosp Pharm (1988) 18, 289–92.
Worden JP, Wood CA, Workman CH. Phenytoin and nasogastric feedings. Neurology (1984) 34, 132.
Hatton RC. Dietary interaction with phenytoin. Clin Pharm (1984) 3, 110–11.
Weinryb J, Cogen R. Interaction of nasogastric phenytoin and enteral feeding solution. J Am Geriatr Soc (1989) 37, 195–6.
Maynard GA, Jones KM, Guidry JR. Phenytoin absorption from tube feedings. Arch Intern Med (1987) 147, 1821.
Doak KK, Haas CE, Dunnigan KJ, Reiss RA, Reiser JR, Huntress J, Altavela JL. Bioavailability of phenytoin acid and phenytoin sodium with enteral feedings. Pharmacotherapy (1998) 18, 637–45.
Rodman DP, Stevenson TL, Ray TR. Phenytoin malabsorption after jejunostomy tube delivery. Pharmacotherapy (1995) 15, 801–5.
Miller SW, Strom JG. Stability of phenytoin in three enteral nutrient formulas. Am J Hosp Pharm (1988) 45, 2529–32.
Hooks MA, Longe RL, Taylor AT, Francisco GE. Recovery of phenytoin from an enteral nutrient formula. Am J Hosp Pharm (1986) 43, 685–8.
Krueger KA, Garnett WR, Comstock TJ, Fitzsimmons WE, Karnes HT, Pellock JM. Effect of two administration schedules of an enteral nutrient formula on phenytoin bioavailability. Epilepsia (1987) 28, 706–12.
Fleisher D, Sheth N, Kou JH. Phenytoin interaction with enteral feedings administered through nasogastric tubes. J Parenter Enteral Nutr (1990) 14, 513–16.
Gilbert S. How to minimize interaction between phenytoin and enteral feedings: two approaches. A Strategic approach. Nutr Clin Pract (1996) 11, 28–30.
Faraji B, Yu P-P. Serum phenytoin levels of patients on gastrostomy tube feeding. J Neurosci Nurs (1998) 30, 55–9.
Hatton J, Magnuson B. How to minimize interaction between phenytoin and enteral feedings: two approaches. B Therapeutic options. Nutr Clin Pract (1996) 11, 30–1.
Issy AM, Lanchote VL, de Carvalho D, Silva HC. Lack of kinetic interaction between valproic acid and citrus pectin. Ther Drug Monit (1997) 19, 516–20.
Shellenberger K, Wallace J, Groves L. Effect of food on pharmacokinetics of zonisamide in healthy volunteers. Epilepsia (1998) 39 (Suppl 6), 191.
Gunnarsson P O, Davidsson T, Andersson S-B, Backman C, Johansson S-Å. Impairment of estramustine phosphate absorption by concurrent intake of milk and food. Eur J Clin Pharmacol (1990) 38, 189–93.
Harvey VJ, Slevin ML, Joel SP, Johnston A, Wrigley PFM. The effect of food and concurrent chemotherapy on the bioavailability of oral etoposide. Br J Cancer (1985) 52, 363–7.
Reece PA, Kotasek D, Morris RG, Dale BM, Sage RE. The effect of food on oral melphalan absorption. Cancer Chemother Pharmacol (1986) 16, 194–7.
Pinkerton CR, Welshman SG, Glasgow JFT, Bridges JM. Can food influence the absorption of methotrexate in children with acute lymphoblastic leukaemia? Lancet (1980) 2, 944–6.
Madanat F, Awidi A, Shaheen O, Ottman S, Al-Turk W. Effects of food and gender on the pharmacokinetics of methotrexate in children. Res Commun Chem Pathol Pharmacol (1987) 55, 279–82.
Kozloski GD, De Vito JM, Kisicki JC, Johnson JB. The effect of food on the absorption of methotrexate sodium tablets in healthy volunteers. Arthritis Rheum (1992) 35, 761–4.
Riccardi R, Balis FM, Ferrara P, Lasorella A, Poplak DG, Mastrangelo R. Influence of food intake on bioavailability of oral 6-mercaptopurine in children with acute lymphoblastic leukaemia. J Pediatr Hematol Oncol (1986) 3, 319–24.
Burton NK, Barnett MJ, Aherne GW, Evans J, Douglas I, Lister TA. The effect of food on the oral administration of 6-mercaptopurine. Cancer Chemother Pharmacol (1986) 18, 90–1.
Lönnerholm G, Kreuger A, Lindström B, Myrdal U. Oral mercaptopurine in childhood leukemia: influence of food intake on bioavailability. Pediatr Hematol Oncol (1989) 6, 105–12.
Kopitar Z, Vrhovac B, Povšič L, Plavšić F, Francetić I, Urbančič J. The effect of food and metoclopramide on the pharmacokinetics and side effects of bromocriptine. Eur J Drug Metab Pharmacokinet (1991) 16, 177–81.
Persiani S, Rocchetti M, Pacciarini MA, Holt B, Toon S, Strolin-Benedetti M. The effect of food on cabergoline pharmacokinetics and tolerability in healthy volunteers. Biopharm Drug Dispos (1996) 17, 443–55.
Gandon JM, Le Coz F, Kühne G, Hümpel M, Allain H. PK/PD interaction studies of lisuride with erythromycin and food in healthy volunteers. Clin Pharmacol Ther (1995) 57, 191.
Morgan JP, Bianchine JR, Spiegel HE, Nutley NJ, Rivera-Calimlim L, Hersey RM. Metabolism of levodopa in patients with Parkinson’s disease. Arch Neurol (1971) 25, 39–44.
Robertson DRC, Higginson I, Macklin BS, Renwick AG, Waller DG, George CF. The influence of protein containing meals on the pharmacokinetics of levodopa in healthy volunteers. Br J Clin Pharmacol (1991) 31, 413–17.
Gillespie NG, Mena I, Cotzias GC, Bell MA. Diets affecting treatment of parkinsonism with levodopa. J Am Diet Assoc (1973) 62, 525–8.
Juncos JL, Fabbrini G, Mouradian MM, Serrati C, Chase TN. Dietary influences on the antiparkinsonian response to levodopa. Arch Neurol (1987) 44, 1003–1005.
Carter JH, Nutt JG, Woodward WR, Hatcher LF, Trotman TL. Amount and distribution of dietary protein affects clinical response to levodopa in Parkinson’s disease. Neurology (1989) 39, 552–6.
Pearce LA, Waterbury LD. L-methionine: a possible levodopa antagonist. Neurology (1974) 24, 640–1.
Weitbrecht W-U, Weigel K. Der einfluß von L-tryptophan auf die L-dopa-resorption. Dtsch Med Wochenschr (1976) 101, 20–2.
Daniel PM, Moorhouse SR, Pratt OE. Do changes in blood levels of other aromatic aminoacids influence levodopa therapy? Lancet (1976) i, 95.
Bramer SL, Forbes WP. Relative bioavailability and effects of a high fat meal on single dose cilostazol pharmacokinetics. Clin Pharmacokinet (1999) 37 (Suppl 2), 13–23.
Shah J, Fratis A, Ellis D, Murakami S, Teitelbaum P. Effect of food and antacid on absorption of orally administered ticlopidine hydrochloride. J Clin Pharmacol (1990) 30, 733–6.
Mallikaarjun S, Riesgo Y, Salazar F, Bramer S, Xie J, Weston I. Time of dosing and food effect on aripiprazole pharmacokinetics. Eur Neuropsychopharmacol (2003) S332.
Bareggi SR, Pirola R, Truci G, Leva S, Smirna S. Effect of after-dinner administration on the pharmacokinetics of oral flunitrazepam and loprazolam. J Clin Pharmacol (1988) 28, 371–5.
Yasui-Furukori N, Takahata T, Kondo T, Mihara K, Kaneko S, Tateishi T. Time effects of food intake on the pharmacokinetics and pharmacodynamics of quazepam. Br J Clin Pharmacol (2003) 55, 382–8.
Kim Y, Morikawa M, Ohsawa H, Kou M, Ishida E, Igarashi J, Kajimoto T, Danno T, Nakata M, Yokoyama T, Tokuyama A, Nakamura Y, Kishimoto T. Effects of food on the pharmacokinetics and clinical efficacy of quazepam. Jpn J Neuropsychopharmacol (2003) 23, 205–10.
Yasui-Furukori N, Kondo T, Takahata T, Mihara K, Ono S, Kaneko S, Tateishi T. Effect of dietary fat content in meals on pharmacokinetics of quazepam. J Clin Pharmacol (2002) 42, 1335–40.
Abel S, Van der Ryst E, Muirhead GJ, Rosario M, Edgington A, Weissgerber G. Pharmacokinetics of single and multiple oral doses of UK-427,857—a novel CCR5 antagonist in healthy volunteers. 10 th Conference on Retroviruses and Opportunistic Infections, Boston MA, Feb 10–14, 2003. Available at: http://www.retroconference.org/2003/cd/Abstract/547.htm (accessed 21/08/07).
Morse GD, Fischl MA, Cox SR, Thompson L, Della-Coletta AA, Freimuth WW. Effect of food on the steady-state (SS) pharmacokinetics of delavirdine mesylate (DLV) in HIV+ patients. Intersci Conf Antimicrob Agents Chemother (1995) 35, 210.
Cox SR, Della-Coletta AA, Turner SW, Freimuth WW. Single-dose pharmacokinetic (PK) studies with delavirdine (DLV) mesylate: dose proportionality and effects of food and antacid. Intersci Conf Antimicrob Agents Chemother (1994) 34, 82.
Lamson MJ, Cort S, Sabo JP, MacGregor TR, Keirns JJ. Effects of food or antacid on the bioavailability of nevirapine 200 mg in 24 healthy volunteers. Pharm Res (1995) 12 (9 Suppl), S-101.
Knupp CA, Milbrath R, Barbhaiya RH. Effect of time of food administration on the bioavailability of didanosine from a chewable tablet formulation. J Clin Pharmacol (1993) 33, 568–73.
Shyu WC, Knupp CA, Pittman KA, Dunkle L, Barbhaiya RH. Food-induced reduction in bioavailability of didanosine. Clin Pharmacol Ther (1991) 50, 503–7.
Hartman NR, Yarchoan R, Pluda JM, Thomas RV, Wyvill KM, Flora KP, Broder S, Johns DG. Pharmacokinetics of 2′,3′-dideoxyinosine in patients with severe human immunodeficiency infection. The effects of different oral formulations and the presence of other medications. Clin Pharmacol Ther (1991) 50, 278–85.
Lotterer E, Ruhnke M, Trautmann M, Beyer R, Bauer FE. Decreased and variable systemic availability of zidovudine in patients with AIDS if administered with a meal. Eur J Clin Pharmacol (1991) 40, 305–8.
Ruhnke M, Bauer FE, Seifert M, Trautmann M, Hille H, Koeppe P. Effects of standard breakfast on pharmacokinetics of oral zidovudine in patients with AIDS. Antimicrob Agents Chemother (1993) 37, 2153–8.
Unadkat JD, Collier AC, Crosby SS, Cummings D, Opheim KE, Corey L. Pharmacokinetics of oral zidovudine (azidothymidine) in patients with AIDS when administered with and without a high-fat meal. AIDS (1990) 4, 229–32.
Hollister AS, Frazer HA. The effects of a high fat meal on the serum pharmacokinetics of sustained-release zidovudine. Clin Pharmacol Ther (1994) 55, 193.
Sahai J, Gallicano K, Garber G, McGilveray I, Hawley-Foss N, Turgeon N, Cameron DW. The effect of a protein meal on zidovudine pharmacokinetics in HIV-infected patients. Br J Clin Pharmacol (1992) 33, 657–60.
Carver PL, Fleisher D, Zhou SY, Kaul D, Kazanjian P, Li C. Meal composition effects on the oral bioavailability of indinavir in HIV-infected patients. Pharm Res (1999) 16, 718–24.
Stone JA, Ju WD, Steritt A, Woolf EJ, Yeh KC, Deutsch P, Waldman S, Bjornsson TD. Effect of food on the pharmacokinetics of indinavir in man. Pharm Res (1996) 13 (Suppl 9), S414.
Quart BD, Chapman SK, Peterkin J, Webber S, Oliver S. Phase I safety, tolerance, pharmacokinetics and food effect studies of AG1343--a novel HIV protease inhibitor. The American Society for Microbiology in collaboration with NIH and CDC. 2 nd National Conference Human Retroviruses and Related Infections, Washington DC (1995). Abstract LB3.
Bertz R, Shi H, Cavanaugh J, Hsu A. Effect of three vehicles, Advera ® , Ensure ® and chocolate milk, on the bioavailability of an oral liquid formulation of Norvir (Ritonavir). Intersci Conf Antimicrob Agents Chemother (1996) 36, 5.
Zhou X-J, Lloyd DM, Chao GC, Brown NA. Absence of food effect on the pharmacokinetics of telbivudine following oral administration in healthy subjects. J Clin Pharmacol (2006) 46, 275–81.
Melander A, Danielson K, Scherstén B, Wåhlin E. Enhancement of the bioavailability of propranolol and metoprolol by food. Clin Pharmacol Ther (1977) 22, 108–12.
Liedholm H, Melander A. Concomitant food intake can increase the bioavailability of propranolol by transient inhibition of its presystemic primary conjugation. Clin Pharmacol Ther (1986) 40, 29–36.
McLean AJ, Isbister C, Bobik A, Dudley F. Reduction of first-pass hepatic clearance of propranolol by food. Clin Pharmacol Ther (1981) 30, 31–4.
Daneshmend TK, Roberts CJC. The influence of food on the oral and intravenous pharmacokinetics of a high clearance drug: a study with labetalol. Br J Clin Pharmacol (1982) 14, 73–8.
Dawes CP, Kendall MJ, Welling PG. Bioavailability of conventional and slow-release oxprenolol in fasted and nonfasted individuals. Br J Clin Pharmacol (1979) 7, 299–302.
John VA, Smith SE. Influence of food intake on plasma oxprenolol concentrations following oral administration of conventional and Oros preparations. Br J Clin Pharmacol (1985) 19, 191S–195S.
Kiger JL, Lavene D, Guillaume MF, Guerret M, Longchampt J. The effect of food and clopamide on the absorption of pindolol in man. Int J Clin Pharmacol Biopharm (1976) 13, 228–32.
Melander A, Stenberg P, Liedholm H, Scherstén B, Wåhlin-Boll E. Food-induced reduction in bioavailability of atenolol. Eur J Clin Pharmacol (1979) 16, 327–30.
Barnwell SG, Laudanski T, Dwyer M, Story MJ, Guard P, Cole S, Attwood D. Reduced bioavailability of atenolol in man: the role of bile acids. Int J Pharmaceutics (1993) 89, 245–50.
Faulkner JK, Hayden ML, Chasseaud LF, Taylor T. Absorption of amlodipine unaffected by food. Solid dose equivalent to solution dose. Arzneimittelforschung (1989) 39, 799–801.
Du Souich P, Lery N, Lery L, Varin F, Boucher S, Vezina M, Pilon D, Spenard J, Caillé G. Influence of food on the bioavailability of diltiazem and two of its metabolites following the administration of conventional tablets and slow-release capsules. Biopharm Drug Dispos (1990) 11, 137–47.
Bianchetti G, Bagheri H, Houin G, Dubruc C, Thénot JP. Pharmacokinetic and bioavailability of diltiazem sustained-release: influence of food and time of administration. Fundam Clin Pharmacol (1995) 9, 197–201.
Holmes DG, Kutz K. Bioequivalence of a slow-release and a non-retard formulation of isradipine. Am J Hypertens (1993) 6 (3 Pt 2), 70S–73S.
Rosillon D, Stockis A, Poli G, Acerbi D, Lins R, Jeanbaptiste B. Food effect on the oral bioavailability of manidipine: single dose, randomized, crossover study in healthy male subjects. Eur J Drug Metab Pharmacokinet (1998) 23, 197–202.
Ochs HR, Rämsch K-D, Verburg-Ochs B, Greenblatt DJ, Gerloff J. Nifedipine: kinetics and dynamics after single oral doses. Klin Wochenschr (1984) 62, 427–9.
Reitberg DP, Love SJ, Quercia GT, Zinny MA. Effect of food on nifedipine pharmacokinetics. Clin Pharmacol Ther (1987) 42, 72–5.
Challenor VF, Waller DG, Gruchy BS, Renwick AG, George CF. Food and nifedipine pharmacokinetics. Br J Clin Pharmacol (1987) 23, 248–9.
Rimoy GH, Idle JR, Bhaskar NK, Rubin PC. The influence of food on the pharmacokinetics of ‘biphasic’ nifedipine at steady state in normal subjects. Br J Clin Pharmacol (1989) 28, 612–15.
Schug BS, Brendel E, Wonnemann M, Wolf D, Wargenau M, Dingler A, Blume HH. Dosage form-related food interaction observed in a marketed once-daily nifedipine formulation after a high-fat American breakfast. Eur J Clin Pharmacol (2002) 58, 119–25.
Devane JG, Kelly JG. Effect of food on the bioavailability of a multiparticulate sustained-release verapamil formulation. Adv Therapy (1991) 8, 48–53.
Dingemanse J, Bodin F, Weidekamm E, Kutz K, van Giersbergen P. Influence of food intake and formulation on the pharmacokinetics and metabolism of bosentan, a dual endothelin receptor antagonist. J Clin Pharmacol (2002) 42, 283–9.
Melander A, Danielson K, Hanson A, Rudell B, Schersten B, Thulin T, Wåhlin E. Enhancement of hydralazine bioavailability by food. Clin Pharmacol Ther (1977) 22, 104–7.
Liedholm H, Wåhlin-Boll E, Hanson A, Melander A. Influence of food on the bioavailability of ‘real’ and ‘apparent’ hydralazine from conventional and slow-release preparations. Drug Nutr Interact (1982) 1, 293–302.
Walden RJ, Hernadez R, Witts D, Graham BR, Prichard BN. Effect of food on the absorption of hydralazine in man. Eur J Clin Pharmacol (1981) 20, 53–8.
Shepherd AM, Irvine NA, Ludden TM. Effect of food on blood hydralazine levels and response in hypertension. Clin Pharmacol Ther (1984) 36, 14–18.
Jackson SHD, Shepherd AMM, Ludden TM, Jamieson MJ, Woodworth J, Rogers D, Ludden LK, Muir KT. Effect of food on oral bioavailability of apresoline and controlled release hydralazine in hypertensive patients. J Cardiovasc Pharmacol (1990) 16, 624–8.
Semple HA, Koo W, Tam YK, Ngo LY, Coutts RT. Interactions between hydralazine and oral nutrients in humans. Ther Drug Monit (1991) 13, 304–8.
Beermann B, Midskov C. Reduced bioavailability and effect of furosemide given with food. Eur J Clin Pharmacol (1986) 29, 725–7.
McCrindle JL, Li Kam Wa TC, Barron W, Prescott LF. Effect of food on the absorption of frusemide and bumetanide in man. Br J Clin Pharmacol (1996) 42, 743–6.
Hammarlund MM, Paalzow LK, Odlind B. Pharmacokinetics of furosemide in man after intravenous and oral administration. Application of moment analysis. Eur J Clin Pharmacol (1984) 26, 197–207.
Kelly MR, Cutler RE, Forrey AW, Kimpel BM. Pharmacokinetics of orally administered furosemide. Clin Pharmacol Ther _ (1974) 15, 178–86.
Paintaud G, Alván G, Eckerna s SÅ, Wakelkamp M, Grahnén A. The influence of food intake on the effect of two controlled release formulations of furosemide. Biopharm Drug Dispos (1995) 16, 221–32.
Melander A, Danielson K, Schersten B, Thulin T, Wåhlin E. Enhancement by food of canrenone bioavailability from spironolactone. Clin Pharmacol Ther (1977) 22, 100–3.
Thulin T, Wåhlin-Boll E, Liedholm H, Lindholm L, Melander A. Influence of food intake on antihypertensive drugs: spironolactone. Drug Nutr Interact (1983) 2, 169–73.
Overdiek HW, Merkus FW. Influence of food on the bioavailability of spironolactone. Clin Pharmacol Ther (1986) 40, 531–6.
Matzek KM, MacGregor TR, Keirns JJ, Vinocur M. Effect of food and antacids on the oral absorption of pirenzepine in man. Int J Pharmaceutics (1986) 28, 151–5.
Andersson T, Magner D, Patel J, Rogers P, Levine JG. Esomeprazole 40 mg capsules are bioequivalent when administered intact or as the contents mixed with applesauce. Clin Drug Invest (2001) 21, 67–71.
Johnson DA, Roach AC, Carlsson AS, Karlsson AAS, Behr DE. Stability of esomeprazole capsule contents after in vitro suspension in common soft foods and beverages. Pharmaco-therapy (2003) 23, 731–4.
Delhotal-Landes B, Cournot A, Vermerie N, Dellatolas F, Benoit M, Flouvat B. The effect of food and antacids on lansoprazole absorption and disposition. Eur J Drug Metab Pharmacokinet (1991), Spec No 3, 315–20.
Bergstrand R, Grind M, Nyberg G, Olofsson B. Decreased oral bioavailability of lansoprazole in healthy volunteers when given with a standardised breakfast. Clin Drug Invest (1995) 9, 67–71.
Chun AHC, Erdman K, Chiu YL, Pilmer BL, Achari R, Cavanaugh JH. Bioavailability of lansoprazole granules administered in juice or soft food compared to the intact capsule formulation. Clin Ther (2002) 24, 1322–31.
Rohss K, Andren K, Heggelund A, Lagerstrom P-O, Lundborg P. Bioavailability of omeprazole given in conjunction with food. III World Conf Clin Pharmacol Ther, Stockholm July-Aug 1986. Acta Pharmacol Toxicol (Copenh) (1986) 85 (Suppl 5), Abstract 207.
Thomson ABR, Sinclair P, Matisko A, Rosen E, Andersson T, Olofsson B. Influence of food on the bioavailability of an enteric-coated tablet formulation of omeprazole under repeated dose conditions. Can J Gastroenterol (1997) 11, 663–7.
Keogh A, Day R, Critchley L, Duggin G, Baron D. The effect of food and cholestyramine on the absorption of cyclosporine in cardiac transplant recipients. Transplant Proc (1988) 20, 27–30.
Gupta SK, Benet LZ. Food increases the bioavailability of cyclosporin in healthy volunteers. Clin Pharmacol Ther (1989) 45,148.
Ptachcinski RJ, Venkataramanan R, Rosenthal JT, Burckart GJ, Taylor RJ, Hakala TR. The effect of food on cyclosporine absorption. Transplantation (1985) 40, 174–6.
Santos P, Lourenço R, Camilo ME, Oliveira AG, Figueira I, Pereira ME, Ferreira B, Carmo JA, Lacerda JMF. Parenteral nutrition and cyclosporine: do lipids make a difference? A prospective randomized crossover trial. Clin Nutr (2001) 20, 31–6.
Johnston PE, Milstone A. Probable interaction of bergamottin and cyclosporine in a lung transplant recipient. Transplantation (2005) 79, 746.
Schwarz UI, Johnston PE, Bailey DG, Kim RB, Mayo G, Milstone A. Impact of citrus soft drinks relative to grapefruit juice on ciclosporin disposition. Br J Clin Pharmacol (2005) 62, 485–91.
Sirtori M, Pazzucconi F, Gianfranceschi G, Sirtori CR. Efficacy of cholestyramine does not vary when taken before or during meals. Atherosclerosis (1991) 88, 249–52.
Lohmann A, Dingler E, Sommer W. Influence of food on the bioavailability of theophylline from a sustained-release theophylline preparation. Arzneimittelforschung (1991) 41, 732–4.
Vaughan L, Milavetz G, Hill M, Weinberger M, Hendeles L. Food-induced dose-dumping of Theo-24, a ‘once-daily’ slow-release theophylline product. Drug Intell Clin Pharm (1984) 18, 510.
Johansson Ö, Lindberg T, Melander A, Wåhlin-Boll E. Different effects of different nutrients on theophylline absorption in man. Drug Nutr Interact (1985) 3, 205–11.
Sips AP, Edelbroek PM, Kulstad S, de Wolff FA, Dijkman JH. Food does not effect bioavailability of theophylline from Theolin Retard. Eur J Clin Pharmacol (1984) 26, 405–7.
Steffensen G, Pedersen S. Food induced changes in theophylline absorption from a once-a-day theophylline product. Br J Clin Pharmacol (1986) 22, 571–7.
Ürmös I, Grézal G, Balogh Nemes K, Szállási T, Drabant S, Csörgo M, Klebovich I. Food interaction study of a new theophylline (Egifilin) 200 and 400 mg retard tablet in healthy volunteers. Int J Clin Pharmacol Ther (1997) 35, 65–70.
González MA, Straughn AB. Effect of meals and dosage-form modification on theophylline bioavailability from a 24-hour sustained-release delivery system. Clin Ther (1994) 16, 804–14.
Thebault JJ, Aiache JM, Mazoyer F, Cardot JM. The influence of food on the bioavailability of a slow release theophylline preparation. Clin Pharmacokinet (1987) 13, 267–72.
Lefebvre RA, Belpaire FM, Bogaert MG. Influence of food on steady state serum concentrations of theophylline from two controlled-release preparations. Int J Clin Pharmacol Ther Toxicol (1988) 26, 375–9.
Fassihi AR, Dowse R, Robertson SSD. Effect of dietary cellulose on the absorption and bioavailability of theophylline. Int J Pharmaceutics (1989) 50, 79–82.
Kappas A, Anderson KE, Conney AH, Alvares AP. Influence of dietary protein and carbohydrate on antipyrine and theophylline metabolism in man. Clin Pharmacol Ther (1976) 20, 643–53.
Feldman CH, Hutchinson VE, Pippenger CE, Blumenfeld TA, Feldman BR, Davis WJ. Effect of dietary protein and carbohydrate on theophylline metabolism in children. Pediatrics (1980) 66, 956–62.
Thompson PJ, Skypala I, Dawson S, McAllister WAC, Turner Warwick M. The effect of diet upon serum concentrations of theophylline. Br J Clin Pharmacol (1983) 16, 267–70.
Anderson KE, McCleery RB, Vesell ES, Vickers FF, Kappas A. Diet and cimetidine induce comparable changes in theophylline metabolism in normal subjects. Hepatology (1991) 13, 941–6.
Bouraoui A, Toumi A, Bouchahcha S, Boukef K, Brazier JL. Influence de l’alimentation épicée et piquante sur l’absorption de la théophylline. Therapie (1986) 41, 467–71.
Gal P, Layson R. Interference with oral theophylline absorption by continuous nasogastric feedings. Ther Drug Monit (1986) 8, 421–3.
Bhargava VO, Schaaf LJ, Berlinger WG, Jungnickel PW. Effect of an enteral nutrient formula on sustained-release theophylline absorption. Ther Drug Monit (1989) 11, 515–19.
Plezia PM, Thornley SM, Kramer TH, Armstrong EP. The influence of enteral feedings on sustained-release theophylline absorption. Pharmacotherapy (1990) 10, 356–61.
Ziegenbein RC. Theophylline clearance increase from increased amino acid in a CPN regimen. Drug Intell Clin Pharm (1987) 21, 220–1.
Cuddy PG, Bealer JF, Lyman EL, Pemberton LB. Theophylline disposition following parenteral feeding of malnourished patients. Ann Pharmacother (1993) 27, 846–51.
Pantuck EJ, Pantuck CB, Garland WA, Min BH, Wattenberg LW, Anderson KE, Kappas A, Conney AH. Stimulatory effect of Brussels sprouts and cabbage on human drug metabolism. Clin Pharmacol Ther (1979) 25, 88–95.
Kleman MI, Overvik E, Poellinger L, Gustafsson JA. Induction of cytochrome P4501A isoenzymes by heterocyclic amines and other food-derived compounds. Princess Takamatsu Symp (1995) 23, 163–71.
Kappas A, Alvares AP, Anderson KE, Pantuck EJ, Pantuck CB, Chang R, Conney AH. Effect of charcoal-broiled beef on antipyrine and theophylline metabolism. Clin Pharmacol Ther (1979) 23, 445–50.
Peng W-X, Li H-D, Zhou H-H. Effect of daidzein on CYP1A2 activity and pharmacokinetics of theophylline in healthy volunteers. Eur J Clin Pharmacol (2002) 59, 237–41.
Greb WH, Brett MA, Buscher G, Dierdorf H-D, von Schrader HW, Wolf D, Mellows G, Zussman BD. Absorption of paroxetine under various dietary conditions and following antacid intake. Acta Psychiatr Scand (1989) 80 (Suppl 350), 99–101.
Stewart DE. High-fiber diet and serum tricyclic antidepressant levels. J Clin Psychopharmacol (1992) 12, 438–40.
Abernethy DR, Divoll M, Greenblatt DJ, Shader RI. Imipramine pharmacokinetics and absolute bioavailability: effect of food. Clin Res (1983) 31, 626A.
Liedholm H, Lidén A. Food intake and the presystemic metabolism of single doses of amitriptyline and nortriptyline. Fundam Clin Pharmacol (1998) 12, 636–42.
Bozigian HP, Pritchard JF, Gooding AE, Pakes GE. Ondansetron absorption in adults: effect of dosage form, food, and antacids. J Pharm Sci (1994) 83, 1011–13.
Schuna A, Osman MA, Patel RB, Welling PG, Sundstrom WR. Influence of food on the bioavailability of penicillamine. J Rheumatol (1983) 10, 95–7.
Osman MA, Patel RB, Schuna A, Sundstrom WR, Welling PG. Reduction in oral penicillamine absorption by food, antacid and ferrous sulphate. Clin Pharmacol Ther (1983) 33, 465–70.
Bergstrom RF, Kay DR, Harkcom TM, Wagner JG. Penicillamine kinetics in normal subjects. Clin Pharmacol Ther (1981) 30, 404–13.
McNamara PJ, Jewell RC, Jensen BK, Brindley CJ. Food increases the bioavailability of acitretin. J Clin Pharmacol (1988) 28, 1051–5.
DiGiovanna JJ, Cross EG, McClean SW, Ruddel ME, Gantt G, Peck GL. Etretinate: effect of milk intake on absorption. J Invest Dermatol (1984) 82, 636–40.
Colburn WA, Gibson DM, Rodriguez LC, Buggé CJL, Blumenthal HP. Effect of meals on the kinetics of etretinate. J Clin Pharmacol (1985) 25, 583–9.
Colburn WA, Gibson DM, Wiens RE, Hanigan JJ. Food increases the bioavailability of isotretinoin. J Clin Pharmacol (1983) 23, 534–9.
Borgen LA, Okerholm R, Morrison D, Lai A. The influence of gender and food on the pharmacokinetics of sodium oxybate oral solution in healthy subjects. J Clin Pharmacol (2003) 43, 59–65.
